CERTIFICATE No. GIF-IW-400/0265 01 01/04/142/17



Chief Pharmaceutical Inspector

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

Chief Pharmaceutical Inspector

/the Competent Authority of Poland/

confirms the following:

the manufacturer

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy ul. Ks. Markwarta 8, 85-015 Bydgoszcz, POLAND

site address

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy ul. Ks. Markwarta 8, 85-015 Bydgoszcz, POLAND

has been inspected under the national inspection programme in connection with manufacturing authorisation No. 049/0265/15 in accordance with Art. 40 of Directive 2001/83/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2016, item 2142).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 25-28/04/2017, it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please

contact the issuing authority.

acting Chief Pharmaceutical Inspector

Mewóit

date:

2017 -06- 29

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57

CERTIFICATE No. GIF-IW-400/0265_01_01/04/142/17

Part 2

Human Medicinal Products

| .3 | Biological medicinal products |
|-----|---|
| | 1.3.1 Biological medicinal products |
| | 1.3.1.1 Blood products |
| | 1.3.2 Batch certification |
| | 1.3.2.1 Blood products |
| 1.4 | Other products or processing activity |
| | 1.4.1.3 Other: human plasma for fractionation obtained from whole blood, human plasma for |
| | fractionation obtained by plasmapheresis, hyperimmune plasma |
| .6 | fractionation obtained by plasmapheresis, hyperimmune plasma Quality control testing |

date:

2017 -06- 29

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57 acting Chief Pharmaceutical Impector

Zhigniew Niewojt

CERTIFICATE No. GIF-IW-400/0265 06 01/04/147/17



Chief Pharmaceutical Inspector

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

Chief Pharmaceutical Inspector

/the Competent Authority of Poland/

confirms the following:

the manufacturer

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy ul. Ks. Markwarta 8, 85-015 Bydgoszcz, POLAND

site address

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy Terenowy Oddział w Inowrocławiu

ul. Poznańska 97, 88-100 Inowrocław, POLAND

has been inspected under the national inspection programme in connection with manufacturing authorisation No. 049/0265/15 in accordance with Art. 40 of Directive 2001/83/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2016, item 2142).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 25-28/04/2017, it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please

contact the issuing authority.

octing Chief Pharmaceutical Inspector

date:

2017 -06- 29

Zbigniew Niewójt Chief Pharmaceutical Inspector

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57

CERTIFICATE No. GIF-IW-400/0265_06_01/04/147/17

Part 2

Human Medicinal Products

| 1 MA | MANUFACTURING OPERATIONS | |
|------|---|--|
| 1.3 | Biological medicinal products | |
| | 1.3.1 Biological medicinal products 1.3.1.1 Blood products | |
| 1.4 | Other products or processing activity | |
| | 1.4.1 Manufacture of: 1.4.1.3 Other: human plasma for fractionation obtained by plasmapheresis, hyperimmune plasma | |
| 1.6 | Quality control testing OR FARA | |
| | 1.6.3 Chemical/Physical | |

date:

2017 -06- 2 9

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57 acting Chief Pharmaceutical Inspector

bighiew Niewojt

CERTIFICATE No. GIF-IW-400/0265_05_01/04/146/17



Chief Pharmaceutical Inspector

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

Chief Pharmaceutical Inspector

/the Competent Authority of Poland/

confirms the following:

the manufacturer

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy ul. Ks. Markwarta 8, 85-015 Bydgoszcz, POLAND

site address

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy Terenowy Oddział we Włocławku

ul. Lunewil 15, 87-800 Włocławek, POLAND

has been inspected under the national inspection programme in connection with manufacturing authorisation No. **049/0265/15** in accordance with Art. 40 of Directive 2001/83/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2016, item 2142).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **25-28/04/2017**, it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.

date:

2017 -06- 29

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57 ncting Chief Pharmacoutical Inspector

(. . \ \ . . / ..

kigniew/Niewoit

CERTIFICATE No. GIF-IW-400/0265_05_01/04/146/17

Part 2

Human Medicinal Products

| 1.3 | Biological medicinal products |
|-----|---|
| | 1.3.1 Biological medicinal products |
| | 1.3.1.1 Blood products |
| 1.4 | Other products or processing activity |
| | 1.4.1 Manufacture of: |
| | 1.4.1.3 Other: human plasma for fractionation obtained by plasmapheresis, |
| | hyperimmune plasma |
| 1.6 | Quality control testing 10R FARA |

date:

2017 -06- 29

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57 acting Chief Pharmacentical Inspector

Zbigniew Niewoji

CERTIFICATE No. GIF-IW-400/0265 04 01/04/145/17



Chief Pharmaceutical Inspector

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

Chief Pharmaceutical Inspector

/the Competent Authority of Poland/

confirms the following:

the manufacturer

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy ul. Ks. Markwarta 8, 85-015 Bydgoszcz, POLAND

site address

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy Terenowy Oddział w Brodnicy

ul. 18 Stycznia 36B, 87-300 Brodnica, POLAND

has been inspected under the national inspection programme in connection with manufacturing authorisation No. 049/0265/15 in accordance with Art. 40 of Directive 2001/83/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2016, item 2142).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 25-28/04/2017, it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.

date:

2017 -06- 29

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57

vacting Chief Pharmaceutical Inspector

CERTIFICATE No. GIF-IW-400/0265_04_01/04/145/17

Part 2

Human Medicinal Products

| .3 | Biological medicinal products |
|-----|---|
| | 1.3.1 Biological medicinal products |
| | 1.3.1.1 Blood products |
| 1.4 | |
| | Other products or processing activity |
| | 1.4.1 Manufacture of: |
| | 1.4.1.3 Other: human plasma for fractionation obtained by plasmapheresis, |
| | hyperimmune plasma |
| 1.6 | Quality control testing |
| | 1.6.3 Chemical/Physical |

date:

2017 -06- 29

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57 acting Chief Pharmaceutical Inspector

Zbigniew Niewójt

CERTIFICATE No. GIF-IW-400/0265_03_01/04/144/17



Chief Pharmaceutical Inspector

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

Chief Pharmaceutical Inspector

/the Competent Authority of Poland/

confirms the following:

the manufacturer

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy ul. Ks. Markwarta 8, 85-015 Bydgoszcz, POLAND

site address

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy Terenowy Oddział w Toruniu

ul. Św. Józefa 53-59, 87-100 Toruń, POLAND

has been inspected under the national inspection programme in connection with manufacturing authorisation No. 049/0265/15 in accordance with Art. 40 of Directive 2001/83/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2016, item 2142).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 25-28/04/2017, it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please

contact the issuing authority.

asting Chief Pharmaceutical Inspector

date:

2017 -06- 29

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57

GŁÓWNY INSPEKTORAT FARMACEUTYCZNY 2/2

CERTIFICATE No. GIF-IW-400/0265_03_01/04/144/17

Part 2

Human Medicinal Products

| 1.3 | Biological medicinal products |
|-----|--|
| | 1.3.1 Biological medicinal products 1.3.1.1 Blood products |
| 1.4 | Other products or processing activity |
| H T | 1.4.1 Manufacture of: 1.4.1.3 Other: human plasma for fractionation obtained by plasmapheresis, hyperimmune plasma |
| 1.6 | Quality control testing |

date:

2017 -06- 29

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57 acting Chief Pharmaceutical Inspector

V /



Chief Pharmaceutical Inspector

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

Chief Pharmaceutical Inspector

/the Competent Authority of Poland/

confirms the following:

the manufacturer

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy ul. Ks. Markwarta 8, 85-015 Bydgoszcz, POLAND

site address

Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Bydgoszczy Terenowy Oddział w Grudziadzu

ul. Włodka 16-18, 86-300 Grudziądz, POLAND

has been inspected under the national inspection programme in connection with manufacturing authorisation No. 049/0265/15 in accordance with Art. 40 of Directive 2001/83/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2016, item 2142).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 25-28/04/2017, it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please

contact the issuing authority.

date: 2017 -06- 2 9

> Zbigniew Niewójt Chief Pharmaceutical Inspector

Niewójt

acting Chief Pharmy

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57

CERTIFICATE No. GIF-IW-400/0265_02_01/04/143/17

Part 2

Human Medicinal Products

| MANUFACTURING OPERATIONS | |
|--------------------------|---|
| 1.3 | Biological medicinal products |
| | 1.3.1 Biological medicinal products 1.3.1.1 Blood products |
| 1.4 | Other products or processing activity |
| | 1.4.1 Manufacture of: 1.4.1.3 Other: human plasma for fractionation obtained by plasmapheresis, hyperimmune plasma |
| 1.6 | Quality control testing |
| | 1.6.3 Chemical/Physical |

2017 -06- 29 date:

Chief Pharmaceutical Inspectorate ul. Senatorska 12, 00-082 Warszawa, Poland Tel. +48 22 635 99 51, fax. +48 22 635 99 57

acting Chief Pharmaceutical Inspector